TCT 2023 Late-Breaking Science Collection
Published: 09 January 2024
-
Views:
224
-
Likes:
7
-
Views:
224
-
Likes:
7
-
Up Next -
8m 46sPart 3 | Session 3 Four-Year Outcomes from the EVOLUT Low Risk Trial -
11m 22s -
6m 19sPart 3 | Session 5 WATCH-TAVR: WATCHMAN for Patients with AF Undergoing TAVR -
7m 14s
-
25m 48sPart 1 | Session 1 View from the Thoraxcenter: TCT 23 Late-breaking Science Preview Nicolas M Van Mieghem, Joost Daemen
-
30m 36sPart 1 | Session 2 View from the Thoraxcenter: TCT 23 Late-breaking Science Wrap Up Nicolas M Van Mieghem, Joost Daemen
-
8m 13sPart 2 | Session 1 5 Trials That Will Change My Practice With Dr Kendra Grubb Kendra J Grubb
-
14m 10sPart 2 | Session 2 5 Trials That Will Change My Practice With Dr Mirvat Alasnag Mirvat Alasnag
-
12m 36sPart 2 | Session 3 5 Trials That Will Change My Practice With Dr Bernardo Cortese Bernardo Cortese
-
7m 42sPart 3 | Session 1 5Y Outcomes From the PARTNER 3 Low-Risk Trial
Overview
Stay up-to-date with our regular review series, View from the Thoraxcenter hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL). In this #TCT2023 edition they provide a short analysis of the most pertinent data from the late-breaking science presentations.
Short, accessible Expert Interviews were conducted with investigators focusing on study design, key results and applicability of the latest data.
More from this programme
Part 1
View from the Thoraxcenter
Part 2
Highlights
Part 3
Interviews
About the episode
TCT 23 - In this short online interview, we are joined by Dr Robert Yeh (Beth Israel Deaconess Medical Center, US) to discuss the findings of the AGENT IDE trial (NCT04647253), sponsored by Boston Scientific.
AGENT IDE is a prospective, 2:1 randomized multicenter trial that aimed to compare the AGENT paclitaxel-coated balloon to plain-old balloon angioplasty (POBA) with a commercially available PTCA dilation catheter in patients with in-stent restenosis of a previously treated lesion, up to 26mm in length.
600 patients were enrolled in the trial, and were randomised 2:1 to receive either POBA or the AGENT DCB. Results showed that the AGENT DCB was superior to conventional balloon angioplasty in the primary endpoint of target lesion failure at one year (17.9% vs. 28.7%; P=0.006).
Interview Questions:
- What are the unmet needs of ISR patients?
- What are the unique features of the AGENT balloon?
- What was the patient population and study design?
- What were the key findings?
- What are your take-home messages?
- What further study is required?
Recorded remotely from Boston, 2023.
Editor: Jordan Rance
Video Specialist: Oliver Miles
Comments